QD

QuidelOrtho Corporation

QDELHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.73B
-1.9% YoY
Net Income
-$1.13B
+44.8% YoY
EBITDA
-$482.6M
+67.6% YoY
Free Cash Flow
$146.8M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 MACD Negative CrossoverHistogram -0.0179, negative momentum
Aug 28 MACD Positive CrossoverHistogram +0.0922, positive momentum
About QuidelOrtho Corporation

QuidelOrtho Corporation provides diagnostic testing solutions. Valued at $917.5M, QDEL is a small-cap name in its sector. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.

Where QDEL stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, QDEL finished 15.40% below its 150-day moving average ($16.49) and 28.53% below its 200-day moving average ($19.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is QDEL overbought or oversold?

At the September 3, 2026 close, QDEL's RSI(14) was 41.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$917.5M
Fwd P/E9.28
EPS$-15.44
Beta0.68
52W Change-49.4%
ROE-45.9%
Analysis

QuidelOrtho Corporation carries $3.08B in total debt against $123.4M in cash reserves — debt is roughly 24.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $146.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -45.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.4% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $3.27B (2022) to $2.73B (2025), a 16% decline worth watching.

With a beta below 0.7, QuidelOrtho Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for QuidelOrtho Corporation and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms